Charles River: Q4 DSA book-to-bill ~1.1x; acquires K.F. (Cambodia) for $510M and PathoQuest for ~$60M

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2025-FY EPS reported -$2.91 vs consensus $2.37 ▼ miss (-223.0%)

Preliminary Q4 DSA net book-to-bill ~1.1x, driven by improved demand from small/mid biotech and global biopharma in Q4.
2026 organic revenue guidance expects at least flat growth for consolidated and DSA, with revenue growth returning in H2 2026.
Non-GAAP operating margin outlook includes >$100M in incremental cost savings to offset inflation until revenue growth resumes.
Acquiring K.F. (Cambodia) for ~$510M; accretive $0.25 in 2026, $0.60 in 2027; close expected early Q1 2026.
Exercising option to buy remaining 79% of PathoQuest for ~€51.6M (~$60M); close by end Q1 2026, not material to 2026/2027 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.